JP2022502471A - 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤 - Google Patents

化学療法誘発性の悪心および嘔吐を治療するための方法および製剤 Download PDF

Info

Publication number
JP2022502471A
JP2022502471A JP2021520202A JP2021520202A JP2022502471A JP 2022502471 A JP2022502471 A JP 2022502471A JP 2021520202 A JP2021520202 A JP 2021520202A JP 2021520202 A JP2021520202 A JP 2021520202A JP 2022502471 A JP2022502471 A JP 2022502471A
Authority
JP
Japan
Prior art keywords
patient
day
formulation
chemotherapy
thc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021520202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502471A5 (https=
Inventor
ジェイコブソン キャサリン
Original Assignee
ティルレイ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティルレイ，インコーポレイティド filed Critical ティルレイ，インコーポレイティド
Publication of JP2022502471A publication Critical patent/JP2022502471A/ja
Publication of JP2022502471A5 publication Critical patent/JP2022502471A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021520202A 2018-10-10 2019-10-10 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤 Pending JP2022502471A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10
US62/743,839 2018-10-10
PCT/US2019/055662 WO2020077103A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Publications (2)

Publication Number Publication Date
JP2022502471A true JP2022502471A (ja) 2022-01-11
JP2022502471A5 JP2022502471A5 (https=) 2022-10-17

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520202A Pending JP2022502471A (ja) 2018-10-10 2019-10-10 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤

Country Status (12)

Country Link
US (1) US20200113847A1 (https=)
EP (1) EP3863614A1 (https=)
JP (1) JP2022502471A (https=)
KR (1) KR20210116432A (https=)
AU (1) AU2019357608A1 (https=)
BR (1) BR112021006858A2 (https=)
CA (1) CA3115985A1 (https=)
CL (1) CL2021000882A1 (https=)
CO (1) CO2021005797A2 (https=)
MX (1) MX2021004138A (https=)
PE (1) PE20211198A1 (https=)
WO (1) WO2020077103A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024531060A (ja) * 2022-07-06 2024-08-29 アバンサール センディリアン ベルハッド 親油性化合物の改善された経口バイオアベイラビリティを有する自己乳化薬物送達配合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof
CN115968278A (zh) * 2020-05-18 2023-04-14 麦氏生物科技有限公司 脂质-聚合物组合物及使用方法
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529892A (ja) * 2001-03-06 2004-09-30 フォルシュングスインスティトゥート、ヒスチア、フェライン、フユール、クレプスフォルシュング アサ抽出物から製造される医薬組成物
JP2007512373A (ja) * 2003-11-26 2007-05-17 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
JP2016537412A (ja) * 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． テルペン及びカンナビノイドの製剤
US20180085308A1 (en) * 2016-09-27 2018-03-29 CannTab Therapeutics Limited Sustained release cannabinoid formulations
WO2018071581A1 (en) * 2016-10-12 2018-04-19 Columbia Care, Llc An oral composition of extracted cannabinoids and methods of use thereof
WO2018129097A1 (en) * 2017-01-03 2018-07-12 Receptor Life Sciences Medicinal compounds and nutritional supplements
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
JP2021533202A (ja) * 2018-07-31 2021-12-02 オースキャン グループ ホールディングス リミテッド 固体自己乳化医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
WO2006124698A2 (en) * 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CA3025208A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
CA3119786A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
EP3755372A1 (en) * 2018-02-23 2020-12-30 Nicola Michael Spirtos Cannabis based therapeutic and method of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529892A (ja) * 2001-03-06 2004-09-30 フォルシュングスインスティトゥート、ヒスチア、フェライン、フユール、クレプスフォルシュング アサ抽出物から製造される医薬組成物
JP2007512373A (ja) * 2003-11-26 2007-05-17 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
JP2016537412A (ja) * 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． テルペン及びカンナビノイドの製剤
US20180085308A1 (en) * 2016-09-27 2018-03-29 CannTab Therapeutics Limited Sustained release cannabinoid formulations
WO2018071581A1 (en) * 2016-10-12 2018-04-19 Columbia Care, Llc An oral composition of extracted cannabinoids and methods of use thereof
WO2018129097A1 (en) * 2017-01-03 2018-07-12 Receptor Life Sciences Medicinal compounds and nutritional supplements
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
JP2021533202A (ja) * 2018-07-31 2021-12-02 オースキャン グループ ホールディングス リミテッド 固体自己乳化医薬組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTONY J MERSIADES, ET AL: "Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced naus", BMJ OPEN, vol. vol 8, e020745, JPN7023003470, 12 September 2018 (2018-09-12), pages 1 - 8, ISSN: 0005304807 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024531060A (ja) * 2022-07-06 2024-08-29 アバンサール センディリアン ベルハッド 親油性化合物の改善された経口バイオアベイラビリティを有する自己乳化薬物送達配合物
JP7752233B2 (ja) 2022-07-06 2025-10-09 アバンサール センディリアン ベルハッド 親油性化合物の改善された経口バイオアベイラビリティを有する自己乳化薬物送達配合物

Also Published As

Publication number Publication date
WO2020077103A1 (en) 2020-04-16
US20200113847A1 (en) 2020-04-16
CA3115985A1 (en) 2020-04-16
KR20210116432A (ko) 2021-09-27
CL2021000882A1 (es) 2021-08-27
AU2019357608A1 (en) 2021-05-27
MX2021004138A (es) 2021-08-05
BR112021006858A2 (pt) 2021-07-13
PE20211198A1 (es) 2021-07-01
CO2021005797A2 (es) 2021-05-20
EP3863614A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
DK2600851T3 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NEUROPATHIC PAIN
JP7394974B2 (ja) 酢酸アビラテロンを含む医薬組成物、並びにその製造方法及び使用
JP2022502471A (ja) 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤
CZ245198A3 (cs) Použití nikotinu, komplex nikotinu a polyakrylátu a způsob jeho přípravy a farmaceutické kompozice
US20180243308A1 (en) Pharmaceutical combination
US20230330110A1 (en) Hard capsule dosage form and uses thereof
KR20200096538A (ko) 세포 증식성 질환의 치료 또는 예방을 위한 쿠마린 유도체
WO2019100007A1 (en) Cannabinoid compositions
US20200093787A1 (en) Cannabinoid Compositions
CN118715010A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
EP3463298B1 (en) Metronomic oral gemcitabine for cancer therapy
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
US20180153881A1 (en) Dosing Regimens for Fast Onset of Antidepressant Effect
KR20240036651A (ko) 산화성 망막 질환의 진행을 억제하는 방법
US20090054377A1 (en) Compositions and methods for smoking cessation
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
WO2012066347A1 (en) Oil based formulations
AU2015210337B2 (en) Pharmaceutical combination
HK40115748A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.
JP2023513669A (ja) テストステロン含有医薬組成物
Tablets et al. Mechanism of Action
US20150250750A1 (en) Pharmaceutical compostions of diclofenac or salts thereof
HK1185255B (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
HK1185255A (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240416